Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice
Objective: To assess socio-sanitary expenditure after the addition of omalizumab to standard treatment in the control of severe asthma and to analyse its effectiveness under standard clinical practice. Method: Observational retrospective multicentre study conducted in 12 pneumology services in th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-05-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11167.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037855149096960 |
|---|---|
| author | Eva Martínez-Moragón María Climent Eusebi Chiner Cleofé Fernández-Aracil Fernando Sánchez-Toril Inmaculada Lluch-Tortajada |
| author_facet | Eva Martínez-Moragón María Climent Eusebi Chiner Cleofé Fernández-Aracil Fernando Sánchez-Toril Inmaculada Lluch-Tortajada |
| author_sort | Eva Martínez-Moragón |
| collection | DOAJ |
| description | Objective: To assess socio-sanitary expenditure after the addition of omalizumab to standard treatment in the control of severe asthma and to analyse its effectiveness under standard clinical practice.
Method: Observational retrospective multicentre study conducted in 12 pneumology services in the Valencian Community, Spain. Data from 186 patients were analysed. Results of the year before and after the addition of omalizumab were compared. Effectiveness was calculated based on a 3-point increase in the Asthma Control Test and a reduction in the number of annual exacerbations. Utility was calculated by the number of quality adjusted life years. The economic assessment included both direct and indirect costs and results were expressed in terms of incremental cost- effectiveness and incremental cost-utility ratio.
Results: Significant improvements were found in lung function, asthma control, quality of life, and quality adjusted life years between the year before and after the introduction of omalizumab. Taking into account direct and indirect costs, the incremental cost-effectiveness for each avoided exacerbation was € 1,789.28 (95% CI: € 1,019.13-3,038.12) and € 4,569.38 (95% CI: 3,442.86-6,075.05) per 3-point increase in the Asthma Control Test score. The incremental cost-utility ratio per quality adjusted life years gained was € 50,239.98 (95% CI: 37,209.88-68,923.84).
Conclusions: The addition of omalizumab to the treatment regime of patients with severe asthma is effective under standard clinical practice, decreases direct and indirect costs, and provides significant improvements in the health status of patients. |
| format | Article |
| id | doaj-art-e36f904337474befb785a82dae4c7695 |
| institution | DOAJ |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-e36f904337474befb785a82dae4c76952025-08-20T02:56:45ZengElsevierFarmacia Hospitalaria1130-63432171-86952019-05-0143310110910.7399/fh.11167Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practiceEva Martínez-Moragón0María Climent1Eusebi Chiner2Cleofé Fernández-Aracil3Fernando Sánchez-Toril4Inmaculada Lluch-Tortajada5Servicio de Neumología, Hospital Universitario Doctor Peset, Valencia. EspañaServicio de Neumología, Hospital Universitario Doctor Peset, Valencia. EspañaServicio de Neumología, Hospital San Joan, Alicante. EspañaServicio de Neumología, Hospital General de Alicante, Alicante. EspañaServicio de Neumología, Hospital Arnau de Vilanova, Valencia. EspañaServicio de Neumología. Hospital de La Ribera, Valencia. EspañaObjective: To assess socio-sanitary expenditure after the addition of omalizumab to standard treatment in the control of severe asthma and to analyse its effectiveness under standard clinical practice. Method: Observational retrospective multicentre study conducted in 12 pneumology services in the Valencian Community, Spain. Data from 186 patients were analysed. Results of the year before and after the addition of omalizumab were compared. Effectiveness was calculated based on a 3-point increase in the Asthma Control Test and a reduction in the number of annual exacerbations. Utility was calculated by the number of quality adjusted life years. The economic assessment included both direct and indirect costs and results were expressed in terms of incremental cost- effectiveness and incremental cost-utility ratio. Results: Significant improvements were found in lung function, asthma control, quality of life, and quality adjusted life years between the year before and after the introduction of omalizumab. Taking into account direct and indirect costs, the incremental cost-effectiveness for each avoided exacerbation was € 1,789.28 (95% CI: € 1,019.13-3,038.12) and € 4,569.38 (95% CI: 3,442.86-6,075.05) per 3-point increase in the Asthma Control Test score. The incremental cost-utility ratio per quality adjusted life years gained was € 50,239.98 (95% CI: 37,209.88-68,923.84). Conclusions: The addition of omalizumab to the treatment regime of patients with severe asthma is effective under standard clinical practice, decreases direct and indirect costs, and provides significant improvements in the health status of patients.http://www.aulamedica.es/fh/pdf/11167.pdfAsthmaCost-benefit analysisHealth care costsOmalizumabQuality of life |
| spellingShingle | Eva Martínez-Moragón María Climent Eusebi Chiner Cleofé Fernández-Aracil Fernando Sánchez-Toril Inmaculada Lluch-Tortajada Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice Farmacia Hospitalaria Asthma Cost-benefit analysis Health care costs Omalizumab Quality of life |
| title | Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| title_full | Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| title_fullStr | Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| title_full_unstemmed | Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| title_short | Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| title_sort | effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice |
| topic | Asthma Cost-benefit analysis Health care costs Omalizumab Quality of life |
| url | http://www.aulamedica.es/fh/pdf/11167.pdf |
| work_keys_str_mv | AT evamartinezmoragon effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice AT mariacliment effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice AT eusebichiner effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice AT cleofefernandezaracil effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice AT fernandosancheztoril effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice AT inmaculadalluchtortajada effectivenessandpharmacoeconomicanalysisofthetreatmentofsevereasthmawithomalizumabinclinicalpractice |